Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$118.03
neg -2.68
-2.22%
Today's Range: 117.92 - 120.29 | CELG Avg Daily Volume: 5,723,500
Last Update: 03/06/15 - 4:00 PM EST
Volume: 3,993,659
YTD Performance: 7.91%
Open: $120.03
Previous Close: $120.71
52 Week Range: $66.85 - $125.45
Oustanding Shares: 800,590,656
Market Cap: 95,726,624,738
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 15 14 15 16
Moderate Buy 1 1 1 1
Hold 4 4 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.45 1.47 1.28 1.26
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 50.03
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
50.03 50.00 27.74
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.77% 47.89% 230.40%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.90 $1.03 $4.32 $6.09
Number of Analysts 3 3 3 3
High Estimate $0.93 $1.12 $4.47 $7.21
Low Estimate $0.87 $0.98 $4.23 $5.45
Prior Year $0.73 $0.80 $3.36 $4.32
Growth Rate (Year over Year) 23.29% 29.17% 28.57% 40.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Sector could regain its leadership role.
Update
Feb 24, 2015 | 6:51 AM EST
RBC Healthcare Conference

3 Biotech Bounce Trades Real Money Pro($)

Chart setups in Celgene, Medivation and AMAG Pharmaceuticals.
Watch this leadership group that's been lagging.
Bullish
Feb 18, 2015 | 6:55 AM EST
CELG was initiated with a Buy rating, Canaccord Genuity said. $156 price target. Revlimid should drive growth in the next several quart...
The 'dead bodies' are adding up.
For traders? Not so much.

Gilead Posting Decent Gains Real Money Pro($)

Trading in February has commenced and indices started up, but have already given all of their early gains. Americans boosted their savings in December and cut spending by the largest amount in five years.

Getting Defensive Now Real Money Pro($)

I am adding allocation to healthcare.
I don't foresee this announcement as a driver of equities.

Columnist Conversations

I always say avoid the self confident who are full of themselves. The only certainty (in the markets) is the l...
Kudos to Bret "Not George" Jensen today in my Diary. Great job.
The market is coming to terms with the increasing possibility of interest rates moving higher sooner, rather t...
Bonds and notes are taking it on the chin following a much better than expected jobs number. We had been tout...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.